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Abstract
Oxidative stress has been proposed as a potential factor associated with the establishment
and progression of endometriosis. Although a few studies have shown possible mecha-
nisms which may play roles in development, progression of endometriosis, few are known
in regards of initiation of the disease, especially in the relationship with endometrium. The
aim of our study was to investigate whether normal endometrium may be changed by Dam-
age-associated molecular patterns (DAMPs), which may contribute developing pathologic
endometrium to induce endometriosis. Endometrial tissues were obtained from 10 patients
with fibroids undergoing hysterectomy at a university hospital. High mobility group box-1
(HMGB-1), which is a representative DAMP, has been chosen that may induce alteration in
endometrium. In preceding immunohistochemistry experiments using paraffin-block sec-
tions from endometriosis (N = 33) and control (N = 27) group, retrospectively, HMGB-1
expression was shown in both epithelial and stromal cell. HMGB-1 expression was signifi-
cantly increased in secretory phase of endometriosis group, comparing to the controls. To
examine the alteration of endometrial stromal cell (HESC) by oxidative stress in terms of
HMGB-1, cell proliferation and expression of its receptor, TLR4 was measured according to
recombinant HMGB-1 use. Cell proliferation was assessed by CCK-8 assay; real-time PCR
and western blotting were used to quantify Toll like receptor 4 (TLR4) mRNA and protein
expression respectively. A TLR4 antagonist (LPS-RS) and an inhibitor of the NF-κB path-
way (TPCA-1, an IKK-2 inhibitor) were used to confirm the relationships between HMGB-1,
TLR4, and the NF-κB pathway. Passive release of HMGB-1 was significantly proportional to
the increase in cell death (P<0.05). HESCs showed significant proliferation following treat-
ment with rHMGB-1 (P<0.05), and increased TLR4 expression was observed following
rHMGB-1 treatment (P<0.05) in a concentration-dependent manner. Treatment with a TLR4
PLOSONE | DOI:10.1371/journal.pone.0148165 February 12, 2016 1 / 17
OPEN ACCESS
Citation: Yun BH, Chon SJ, Choi YS, Cho S, Lee
BS, Seo SK (2016) Pathophysiology of
Endometriosis: Role of High Mobility Group Box-1
and Toll-Like Receptor 4 Developing Inflammation in
Endometrium. PLoS ONE 11(2): e0148165.
doi:10.1371/journal.pone.0148165
Editor: Siladitya Bhattacharya, University of
Aberdeen, UNITED KINGDOM
Received: September 28, 2015
Accepted: January 13, 2016
Published: February 12, 2016
Copyright: © 2016 Yun et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This research was supported by the Basic
Science Research Program through the National
Research Foundation of Korea (NRF) funded by the
Ministry of Education, Science, and Technology
(NRF-2012R1A1A1013167). The Design of study and
the experiments were modified and supported by
NRF. The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
antagonist and an NF-κB inhibitor resulted in suppression of rHMGB-1-induced HESC pro-
liferation (P<0.05). Levels of IL-6 were significantly decreased following treatment with an
NF-κB inhibitor (P<0.05). Our results support the development of altered, pathological
endometrium resulted from oxidative stress in normal endometrium. These findings may
provide important insights into the changes in endometrium linking the development and
progression of endometriosis.
Introduction
Endometriosis is a gynecological disorder that causes pelvic pain and infertility in women of
reproductive age [1]. While the etiology of the disease remains unclear, retrograde menstrua-
tion, coelomic metaplasia, and lymphovascular metastasis have been shown to be the major
pathological characteristics of endometriosis. However, none of these theories can fully explain
the pathogenesis of endometriosis. Because retrograde menstruation occurs in about 80% of
women, while endometriosis occurs in only 10%–15% of women, additional mechanisms must
contribute to the survival of ectopic endometrium outside the uterus [2].
Oxidative stress has been proposed as a potential factor associated with the establishment
and progression of endometriosis [3,4]. Previous studies have reported that the levels of oxida-
tive stress and antioxidant biomarkers found in peritoneal fluid are significantly different
between patients with and without endometriosis [3]. Moreover, oxidative stress in the pelvic
cavity of patients with endometriosis may be an important facilitator or inducer of chronic
nuclear factor-kappa B (NF-κB) activation, enhancing NF-κB-mediated inflammatory reac-
tions and endometriotic cell survival and growth [4]. Therefore, the vulnerability of the endo-
metrial cells to oxidative stress and the subsequent activation of the oxidative stress-NF-κB
axis may constitute the basis for the pathophysiology of endometriosis.
Damage-associated molecular patterns (DAMPs) are endogenous molecules that can initi-
ate and perpetuate the immune response in noninfectious inflammatory response [5]. High
mobility group box-1 (HMGB-1) is a representative DAMP that is localized in the nucleus of all
mammalian cells [6], where it binds to DNA, stabilizes the structure of DNA, and controls tran-
scriptional activity [7]. However, HMGB-1 may also be released into the extracellular space either
actively by inflammatory cells or passively by necrosis, leading to inflammation [8]. Passively
released HMGB-1 binds to receptors such as Toll-like receptor 4 (TLR4) with high affinity, and
binding of HMGB-1 to TLR4 can activate NF-κB light chain, which play important roles in
tumor growth and progression [9–12]. However, despite these interesting roles of HMGB-1 in
the pathogenesis of various diseases, including sepsis[8], arthritis[13], ischemic injury[14],
researchers are yet to study the involvement of HMGB-1 in endometriosis.
The purpose of this study was to determine whether normal endometrium may be changed
by HMGB-1, acquiring increased cell proliferation and decreased apoptosis. Additionally, we
further investigated whether TLR4 plays an important role in regulating inflammatory
responses by NF-κB pathway in endometrial cells.
Materials and Methods
Participants
FromMarch 2012 to March 2014, total 70 patients who underwent hysterectomies at Severance
Hospital, Yonsei University College of Medicine were enrolled in this study. Among the
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participants, 60 patients were enrolled retrospectively based on their final diagnosis and were
divided into the endometriosis (33 patients) and control (27 patients) groups; the histopatho-
logical slides of endometrial tissues were used for immunohistochemistry. The final diagnosis
of endometriosis was made based on either pathological confirmation of ectopic endometriotic
tissue or operative findings. In the control group, 27 patients had leiomyoma of the uterus, two
had cervical cancer, and one had endometrial stromal nodules. For cell culture, endometrial
specimens were obtained from 10 patients without endometriosis following hysterectomy for
uterine fibroids. All 70 participants were in the reproductive age and had reported having regu-
lar menstrual cycles every 28–30 days. None of the participants received any hormonal treat-
ment for at least 3 months preceding the surgery. The study was approved by the institutional
review board of Severance hospital, Yonsei University College of Medicine (4-2014-0560). 10
participants who provided endometrial tissue for the cell culture were given written informed
consent.
Sample collection
Paraffin-embedded sections of endometrium were provided for immunohistochemistry. The
menstrual cycle phase of the endometrium samples used for immunohistochemistry was char-
acterized by morphological evaluation following the criteria described in a previous publica-
tion[15]: early proliferative (EP), late proliferative (LP), early-secretory (ES), mid-secretory
(MS), late-secretory (LS), and menstrual (M) phases. For each phase, five tissue samples were
included from the endometriosis group, and same for the control group. Endometrial tissue
was obtained by curettage from all of the 10 participants at the beginning of the hysterectomy
process in the operation room. The specimens were transferred into a buffered saline solution
directly after acquisition and immediately sent to the laboratory for analysis.
Study design
The experiments were designed to confirm dynamic expression of HMGB-1 and TLR4 in
endometrium using immunohistochemistry, since there are few data reporting the expression
of HMGB-1 in human endometrium. Separately, endometrial stromal cell culture was per-
formed using endometrial tissue from 10 participants without endometriosis, to examine the
normal stromal cell response to rHMGB-1 and various treatment, in terms of cell proliferation
and TLR4 expression. To examine the passive release of HMGB-1 by necrosis in the endome-
trium, HMGB-1 was examined after inducing cell necrosis by H2O2. Cell death was measured
using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays, and the
levels of HMGB-1 were quantified by enzyme-linked immunosorbent assays (ELISAs) and
western blots. To determine the relationships of HMGB-1 and TLR4 expression with endome-
trial proliferation, cultured endometrial cells were treated with recombinant HMGB-1
(rHMGB-1), which was followed by cell proliferation assay and quantitative real time PCR
(qRT-PCR), western blot for TLR4 RNA and protein expression. To confirm the association of
HMGB-1 and TLR4 in NF-kB pathway, cell proliferation and TLR4 expression were examined
applying TLR4 antagonist (LPS-RS) and inhibitor of NF-kB pathway (TPCA-1, IKK-β inhibi-
tor), adding to rHMGB-1 treatment respectively. In experiment inhibiting NF-kB pathway
with TPCA-1, level of IL-6 was measured to confirm the inhibition and compare with the
appearance of TLR4 expression.
Immunohistochemistry
Paraffin-embedded specimens of endometrium from endometriosis and control groups, were
sectioned at 7μm, prepared with xylene and ethanol, pressurized and heated with proteinase K
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(Welgene, Daegu, Korea) for antigen retrieval. Endogenous peroxidase activity was quenched
with 3% H2O2 for 10 minutes and washed in buffered saline solution (PBS; Welgene, Daegu,
Korea) for 5 minutes twice. Unspecified binding of the first antibody was blocked by 1 hour
incubation step in 5% bovine serum albumin (BSA; Gibco, Invitrogen, Carlsbad, CA, USA).
Slides were incubated in a humidified chamber overnight at 4°C with HMGB-1 rabbit poly-
clonal antibody at 1:100 dilution (ProteinTech, Chicago, IL, USA). Tissue sections were washed
with PBS, tris-buffered saline (TBS; Gibco, Invitrogen) was used for antibody dilutions and
washes. Sections were incubated with rabbit polyclonal secondary antibodies (Vector Laborato-
ries, Burlingame, CA, USA) for 20 min at room temperature. Diaminobenzidine was used as a
chromogen at 1 mg/mL, with 0.3% H2O2 as a substrate. All sections were counterstained with
hematoxylin for 1 min and washed with tap water. After dehydration, mounting was per-
formed. Slides were documented using an Olympus BX 40F-3 microscope (Olympus, Tokyo,
Japan). Intensities of immunoreactive precipitates were scored in epithelial and stromal cell
compartments using Olympus DP controller software.
Interpretation of immunohistochemical staining
The immunohistochemical histological score (H score) was used to show the immunoreactivity
in stained areas of the endometrial glands and stroma, semiquantitatively. The H-score was cal-
culated by the formula [Hscore¼ P(Pi x i)/100], where Pi stands for the percentage of positive
cells for each intensity and i stands for the range of staining intensity. Pi was assigned as fol-
lows: 0 for<5%, 1 for 5% to 25%, 2 for 25% to 50%, 3 for 50% to 75%, and 4 for>75%. The
staining intensity (i) was assigned using a 4-point scale as follows: 0 ¼ negative, 1 ¼ weak, 2 ¼
moderate, and 3 ¼ strong. At least 3 randomly chosen areas from each sample were evaluated
and averaged for each compartment. The scoring procedure was carried out by 2 different,
blinded reviewers without any information about the clinical background.
Cell culture
Human endometrial stromal cells (HESCs) were obtained from tissues of 10 participants, after
washing and sectioning in PBS, followed by treatment with 0.25% trypsin/EDTA (Gibco, Invi-
trogen) for 30 min at 37°C. During the incubation, cells were tapping every 5 min to facilitate
dissociation. Supernatants were removed by centrifugation at 2000 rpm for 5 min, and HESCs
were resuspended in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12, HyClone, Logan,
UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen) and 2% penicil-
lin-streptomycin (P/S; Gibco, Life Technologies, Grand Island, NY, USA). After 1 min, 1 × 106
cells were plated in DMEM/F12 and incubated at 37°C in a 5% CO2 incubator for 24 h.
Measurement of passive HMGB-1 release after induction of necrosis
For measurement of passive HMGB-1 release, 3 × 105 endometrial cells were plated in 6-well
plates. After 24 h of incubation at 37°C, the medium was changed to serum-free DMEM/F12.
Endometrial cells were then incubated with 0, 25, or 50 μMH2O2 for 1 h. Levels of HMBG-1 in
the supernatants were then analyzed by ELISA and western blotting.
MTT assays
MTT solution (100 μL, Sigma) was added to each well, and culture plates were incubated at
37°C for 4 h in a 5% CO2 incubator. The supernatants were harvested for subsequent ELISA
and western blot analysis. After removing medium, 500 μL dimethyl sulfoxide (DMSO; Sigma)
was added to each well, and plates were then incubated for 10 min on a shaker. Finally, the
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optical density (OD) was measured at 562 nm with a VersaMax microplate reader (Molecular
Devices, Sunnyvale, CA, USA).
ELISA
After harvesting supernatants, HMGB-1 was quantified using an HMBG-1 ELISA kit (Shino-
Test Corporation, Kanagawa, Japan), according to the manufacturer’s protocol. The OD was
measured at 450 nm with a VersaMax microplate reader (Molecular Devices). Measurement of
IL-6 (BD Bioscience, San Jose, CA, USA) was performed as a control.
Western blotting
Cells were lysed using radioimmunoprecipitation assay buffer (RIPA buffer; Intron, iNtRON
Biotechnology, Sungnam, Korea) containing protease inhibitor cocktail (Cell Signaling Tech-
nology, Beverly, MA, USA), mixed, and divided in 40-μL aliquots. The lysates were collected
and centrifuged at 13000 rpm at 4°C for 30 min, and protein levels in the supernatants were
quantified using a BCA protein assay kit (Thermo Scientific, Hudson, NH, USA). Western
blotting was then performed using the harvested supernatants. Thirty micrograms of each
lysate was boiled in 5×buffer, and supernatants were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) on 8% gels and transferred to polyvinylidene fluo-
ride (PVDF) membranes (Millipore, Eschborn, Germany). After blocking with BSA at room
temperature for 1 h, the membranes were incubated with primary antibodies specific for
HMGB-1 (monoclonal anti-rabbit, 1:50000; Abcam, Cambridge, MA, USA), TLR4 (polyclonal
anti-rabbit, 0.3 μg/mL, GeneTex, Irvine, CA, USA), and GAPDH (monoclonal anti-mouse,
0.1 μg/mL, Millipore) overnight at 4°C. The membranes were then incubated with anti-mouse
antibodies (IgG, 0.27 μg/mL, Jackson, West Grove, PA, USA) and anti-rabbit antibodies (IgG,
0.27 μg/mL, Jackson) conjugated with horseradish peroxidase (HRP) for 1 h at room tempera-
ture. Detection was facilitated by enhanced chemiluminescence (ECL) solution (Advansta, San
Francisco, CA, USA), and the bands were quantified by densitometry using Image J software.
Cell treatment and proliferation assays (CCK-8 assays)
Endometrial cells were seeded in 6-well tissue culture plates at a density of 1 × 105 cells per
well. The culture medium was changed to DMEM/F12 with 2% FBS after 24 h of incubation.
After changing the media, endometrial cells were treated with rHMGB-1 (Sino, Beijing, China)
at a concentration of 15 ng/mL for 12, 24, or 48 h or treated with rHMGB-1 at concentrations
of 0, 5, 10, or 15 ng/mL for 48 h. For suppression of TLR4, endometrial cells were treated with
100 ng/mL LPS-RS (InvivoGen, San Diego, CA, USA) for 30 min. For suppression of NF-κB,
endometrial cells were treated with 2 μMTPCA-1 (Cayman, Ann Arbor, MI, USA) for 1 h.
Both treatments were followed by rHMGB-1 treatment at concentrations of 0, 5, 10, or 15 ng/
mL for 48 h. Thereafter, 100 μL of CCK-8 (Cell Counting Kit-8; Dojindo, Japan) was added to
each well, and plates were incubated at 37°C for 1 h. Supernatants were transferred to 96-well
plates after incubation, and the OD was measured at 450 nm using a VersaMax microplate
reader (Molecular Devices) to measure cell proliferation rates.
RNA isolation and qRT-PCR
Cell-free total RNA was extracted from cell lysates using an RNeasy mini kit (Qiagen, Hilden,
Germany). cDNA was synthesized from 1 μg total RNA using oligo-dT primers (Invitrogen).
qRT-PCR for TLR4 was carried out using an ABI StepOnePlus (Applied Biosystems, Foster
City, CA, USA) and SYBR green RT PCR master mix (Toyobo, Osaka, Japan). The primers
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used for TLR4 were as follows: 50-CAGAGTTTCCTGCAATGGATCA-30 (sense) and 50-GCT
TATCTGAAGGTGTTGCACAT-30 (antisense), and the primers used for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), which was used as an endogenous reference gene, were
as follows: 50-TCGACAGTCAGCCGCATCTTCTTT-30 (sense) and 50-ACCAAATCCGTTGA
CTCCGACCTT-30 (antisense). The PCR conditions were as follows: 95°C for 10 min, followed
by 40 cycles of 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s. Data were normalized to the
expression of GAPDH, and PCR products were separated on a 1.5% agarose gel containing
ethidium bromide, for quantification by densitometry using Image J software (National Insti-
tutes of Health, USA).
Proinflammatory cytokine measurement
After HESC treating TPCA-1 with rHMGB-1, 2μM of TPCA-1 (Caymen, Ann Arbor, MI,
USA) for 30 minutes, followed by rHMGB-1 treatment with 0, 5, 10, 15ng/mL for 48 hours, the
supernatant was harvested for ELISA. IL-6 was quantified using IL-6 ELISA kit (BD bioscience,
San Jose, CA, USA), according to the manufactures’ protocol. The OD was measured at 450nm
with and ELISA Reader.
Statistical analysis
To determine the significance of difference in the levels of mRNA and protein, Kruskal-Wallis
tests with Dunn’s procedure for multiple comparisons were performed. Statistical analyses
were performed using SPSS 20.0 (IBM, NY, USA). Differences with P values of less than 0.05
were considered statistically significant.
Results
Immunohistochemistry
On immunohistochemistry, the results showed that no significant difference in expression
according to the menstrual cycle, in the control group (Fig 1). HMGB-1 was expressed in both
epithelial and stromal cell in control endometrium. Comparing to the controls, significantly
increased expression of HMGB-1 was shown at early and mid-secretory phase in patients with
endometriosis.
Passive release of HMGB-1 after induction of necrosis in HESCs
To confirm the passive secretion of HMGB-1 induced by cell necrosis, we treated HESCs with
0, 25, or 50 μMH2O2 (Fig 2). MTT assays showed that there was a gradual decrease in cell via-
bility depending on the concentration of H2O2 (Fig 2A). In contrast, secretion of HMGB-1 was
significantly increased in proportion to the concentration of H2O2; HMGB-1 48.00±37.11ng/
mL for 0 μMH2O2, 79.55 ± 36.66ng/mL for 25μMH2O2, and 240.00± 22.26ng/mL for 50μM
H2O2, respectively (Fig 2B–2D).
Effects of rHMGB-1 on cell proliferation and TLR4 expression
Following treatment of HESCs with different concentrations of rHMGB-1 for 0–48 h, cell pro-
liferation was significantly increased in a concentration- (Fig 3 and S1 Fig) and time-dependent
manner (Fig 4 and S1 Fig) as compared with that observed in the control. rHMGB-1 also
caused a concentration- and time-dependent increase in TLR4 mRNA and protein expression.
TLR4 protein expression showed 100.0±2.97% for 0 ng/mL of HMGB-1, 127.63±4.72% for 5
ng/mL of HMGB-1, 208.44±8.09% for 10 ng/mL of HMGB-1, and 296.83±15.20% for 0 ng/mL
of HMGB-1, compared to the GAPDH control, respectively (Fig 3C and 3D). Time-dependent
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Fig 1. Immunohistochemistry analysis of HMGB-1 expression in the human endometrium. In control endometrium, HMGB-1 was expressed in the
glandular cells of the epithelium and in stromal cells (N = 27). No significant differences were observed according to the menstrual cycle (A). In EM from a
patient with endometriosis, significantly increased HMGB-1 expression was detected in the early and mid-secretory phase as compared to the control EM
(N = 33, B). There were no significant differences in HMGB-1 expression between the two groups during the proliferative phase. *, P < 0.05 versus the
control.
doi:10.1371/journal.pone.0148165.g001
HMGB-1 Mediates Inflammation in Human Endometrium
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manner TLR4 protein increase at treatment of rHMGB-1 showed 100.0±6.73% for 0 hour of
HMGB-1, 105.84±3.5% for 12 hours of HMGB-1, 213.88±2.90% 24 hours of HMGB-1, and
Fig 2. Induction of necrosis in HESCs altered the secretion of HMGB-1. Cell viability was detected by MTT assays after treatment of HESCs with H2O2
(A). Extracellular release of HMGB-1 was measured following H2O2-induced necrosis. Relative mRNA (B) and protein levels (C, D) are shown. *, P < 0.05
versus 0 μMH2O2; **, P < 0.05 versus 25 μMH2O2. a, fresh medium was used as a control; b, 0 μMH2O2; c, 25 μMH2O2; d, 50 μMH2O2.
doi:10.1371/journal.pone.0148165.g002
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Fig 3. HESC proliferation and TLR4 expression were altered in a concentration-dependent manner after treatment with rHMGB-1. At 48 h after
treatment with different concentrations of rHMGB-1, cell proliferation was measured (A). Cell proliferation after 24 or 48 h of treatment with rHMGB-1 (B).
Relative mRNA and protein levels of TLR4 are shown following treatment with rHMGB-1 (C, D). *, P < 0.05 versus the control; **, P < 0.05 versus 5 ng/mL
rHMGB-1; ***, P < 0.05 versus 10 ng/mL rHMGB-1.
doi:10.1371/journal.pone.0148165.g003
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271.18±22.35% for 48 hours of HMGB-1 treatment, compared to the GAPDH control, respec-
tively (Fig 4C and 4D).
Fig 4. HESC proliferation and TLR4 expression were altered in a time-dependent manner after treatment with rHMGB-1.Changes in cell proliferation
were measured at 0, 12, 24, and 48 h after treatment with 15 ng/mL rHMGB-1 (A). Relative mRNA (B) and protein levels (C, D) of TLR4 are shown. #,
P < 0.05 versus 12 h; ##, P < 0.05 versus 24 h.
doi:10.1371/journal.pone.0148165.g004
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Effects of combined rHMGB-1 treatment and TLR4 inhibition on cell
proliferation and TLR4 expression
Treatment of HESCs with LPS-RS and rHMGB-1 markedly blocked HESC proliferation com-
pared to the control, although no significant differences were observed among different con-
centrations of rHMGB-1 (S2 Fig and Fig 5A). The combined treatment blocked the rHMGB-
1-induced increases in TLR4 expression, and significantly decreased TLR4 mRNA and protein
levels were observed compared with the control cells at each concentration of rHMGB-1 (Fig
5B–5D). The expression of TLR4 protein according to the LPS-RS and rHMGB-1 treatment
was 24.45±1.68% for 0 ng/mL of HMGB-1, 11.08±0.49% for 5 ng/mL of HMGB-1, 47.94
±1.95% for 10 ng/mL of HMGB-1, 65.57±3.30% for 15 ng/mL of HMGB-1 compared to the
GAPDH control, respectively (Fig 5C and 5D).
Effects of combined rHMGB-1 treatment and NF-κB inhibition on cell
proliferation and TLR4 expression
Next, we analyzed the effects of NF-κB inhibition on cell proliferation and TLR4 expression.
HESCs were treated with TPCA-1 combined with rHMGB-1, and cell proliferation was signifi-
cantly blocked compared with the control (S3 Fig and Fig 6A), similar to the results of TLR4
inhibition. After treatment with TPCA-1 prior to rHMGB-1 in endometrial cells, TLR4 mRNA
and protein levels were significantly decreased compared with that in the control (Fig 6B–6D),
with no concentration-dependent effects observed for rHMGB-1. The protein expression of
TLR4 compared to the control (GAPDH) was shown 67.18±0.50% for 0ng/mL of HMGB-1,
66.90±0.29% for 5ng/mL of HMGB-1, 64.57±0.03% for 10 ng/mL of HMGB-1, and 106.87
±0.18% for 15ng/mL of HMGB-1, respectively. Furthermore, the secretion of IL-6, a pro-
inflammatory cytokine that is known to be the end product of NF-κB pathway activation, was
significantly decreased after treatment with TPCA-1 (Fig 6E).
Discussion
In this study, we sought to elucidate the mechanisms mediating development of pathological
endometrium by oxidative stress in endometriosis. Immunohistochemistry showed presence of
HMGB-1 in human endometrial cells and significantly increased HMGB-1 expression during
secretory phase in endometriosis group compared to the normal controls, additionally. We
found that passively released extracellular HMGB-1 bound to TLR4 and may induce sterile
inflammation via a cascade involving the NF-κB pathway in human endometrium. The effects
of HMGB-1 treatment were blocked by both TLR4 inhibition and NF-κB inhibition, demon-
strating possible involvement of the NF-κB pathway in this mechanism. Based on this, we
developed a model in which DAMPs cooperate in the inflammatory reaction in the HESC by
responding to oxidative stress, which may account for modified ectopic endometrium in pelvic
cavity that lead to endometriosis.
Many studies that were conducted in regards to pathogenesis of endometriosis have been
made various suggestions [16–19]. As well known, the origin of ectopic endometrium is not
agreed in Sampson’s implantation theory, since it does not explain fully in aspects of extra-pel-
vic endometriosis. However, at least in pelvic endometriosis, retrograde menstruation and
implantation on the peritoneal surface leave little for doubt. The mechanism that may contrib-
ute successful ectopic implantation has been suggested as one or two: either or both, molecular
defect and immunological abnormalities [20]. The implanted endometrium may proceed to
induce chronic inflammation by time past, adding burden of iron [21]. The factors that are
related to the progress of the disease are suggested in variety such as epigenetic changes in
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Fig 5. Effects of TLR4 inhibition on HESC proliferation and TLR4 expression following treatment with rHMGB-1. Cells were treated with the TLR4
antagonist LPS-RS, rHMGB-1-induced cell proliferation was measured (A). TLR4 mRNA and protein levels were measured (B–D). *, P < 0.05 versus the
control.
doi:10.1371/journal.pone.0148165.g005
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Fig 6. Effects of NF-κB inhibition on rHMGB-1-induced HESC proliferation and TLR4 expression. The NF-κB pathways was blocked using TPCA-1,
and rHMGB-1-dependent cell proliferation was measured (A). TLR4 expression was analyzed using qRT-PCR (B) and western blotting (C, D) following
treatment with different concentrations of rHMGB-1. Changes in IL-6 secretion were measured following inhibition of the NF-κB pathway by TPCA-1 (E). *,
P < 0.05 versus the control.
doi:10.1371/journal.pone.0148165.g006
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endometriotic tissue, decrease in apoptotic factors, increase in angiogenic factors and cytokines
that resulted in stromal-cell defect and progesterone resistance [16,22]. Although different
character of ectopic endometrium (compared to the eutopic endometrium) has been suggested,
the limitation of it may be that unknown origin of the difference. To say, it is not clear where
the alteration has been occurred–whether the eutopic endometrium has been altered or after
retrograde menstruation, has it been altered? Moreover, the factor which contributes to the
alteration is not clarified, mostly suspected that immunologic factor may affect[17]. Our study
has been started from the question, and the results suggest eutopic endometrium has a poten-
tial of alteration, under the influence of oxidative stress. We have presented a pathway for an
example that may involve the alteration of the endometrium by DAMP, the alteration may be
aggravated in environment with sustained oxidative stress.
Extracellular HMGB-1 is a representative DAMP that acts as an innate ligand sending sig-
nals of cell and tissue damage; other DAMPs include reactive oxygen stress (ROS), heat shock
protein, fibrinogen, and adenosine triphosphate. Secretion of HMGB-1 into the extracellular
space leads to direct binding of HMGB-1 to transmembrane TLR proteins and RAGEs, leading
to NF-κB pathway activation [5,8]. In the pro-oxidant environment, HMGB-1 activates NF-κB
by binding to TLR4 and inducing the pro-inflammatory response. This pathway has been
shown to be involved in the pathogenesis of various diseases, such as rheumatoid arthritis [13],
lupus erythematosus [23], atherosclerosis [24], and sepsis [8]. The pro-inflammatory activity
of HMGB-1 depends on the domain B box, which is composed of two crucial binding sites for
TLR4 and RAGE [25]. The pro-inflammatory activity of HMGB-1 has been shown to be
dependent upon its redox state [26]. In the oxidized environment, e.g., during increased ROS
production, the redox-state of HMGB-1 is necessary to maintain the redox state of the cell
environment. However, the reduction in oxidized HMGB-1 by thioredoxin (TRX) is a slower
reaction than other reducing reactions mediated by TRX [26]. Due to the low efficacy of the
redox system, HMGB-1 may require increased TRX levels to maintain the redox state and
induce the immune reaction. Indeed, previous studies from our lab have shown that the
immune system is dysregulated in the eutopic endometrium of patients with endometriosis
[27]. In the current study, we found that normal, eutopic endometrium may be transformed by
HMGB-1, which may be released by oxidative stress. Because of the sensitivity of HMGB-1 to
the oxidation-reduction state of the surrounding environment, HMGB-1-mediated NF-κB sig-
naling may be the predominant mechanism during early inflammation of the endometrium in
patients with endometriosis. Analysis of TLR4 expression has also supported that the patholog-
ical endometrium affects the development of endometriosis [28].
Additionally, although it was not the primary purpose of this study, we have performed
immunohistochemistry to identify expression of HMGB-1 in endometrial samples from
patients with and without endometriosis (Fig 1). With the exception of a single report of
HMGB-1 expression in rat endometrium, no studies have examined the expression of HMGB-
1 in endometrial tissues [29]. Immunohistochemistry analysis showed that HMGB-1 was
expressed in glandular cells of the epithelium and stromal cells in control endometrium, with-
out significant differences according to the menstrual cycle (Fig 1A). In endometrium from
patients with endometriosis, significantly increased HMGB-1 expression was detected in the
early and mid-secretory phase as compared to the control (Fig 1B). However, it should be
stressed that the meaning of expression and secretion of HMGB-1 is completely different. In
contrast to intracellular HMGB-1, which plays a physiologic role in the nucleus, extracellularly
secreted HMGB-1 acts as a DAMP, resulting in induction of the inflammatory response.
Because of the observed increase in expression in the early and mid-secretory phases, aberrant
expression of HMGB-1 may be associated with interrupted implantation in patients with
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endometriosis, which may partly explain the development of progesterone resistance in
women with endometriosis [30]. Further studies are needed to investigate in terms of this
possibility.
Our study has shown a detailed inflammatory process through which DAMPs and receptors
signal in HESCs. Our results also supported previous findings demonstrating the activation of
the NF-κB pathway in the endometrium of patients with endometriosis and provided support-
ive evidence of the implantation theory, which suggests that the pathologic endometrium is
implanted into the peritoneal cavity, leading to the development of endometriosis. However,
our study was limited in that we only performed in vitro analysis using HESCs. Therefore, in
vivo studies are required using eutopic and ectopic endometrium. Additionally, still remains
unknown that whether the modification of endometrium initiates, inside the endometrial cav-
ity or the pelvic cavity. However, the study gives supporting evidence that oxidative stress may
be a key factor, which develops endometriosis or not in women with retrograde menstruation.
Since the semiquantification of HMGB-1 in endometrium by immunohistochemistry remains
as another limitation, further separated study is required.
In conclusion, our results herein support the development of altered, pathological endome-
trium resulted from oxidative stress in normal endometrium. These findings may provide
important insights into the changes in endometrium linking the development and progression
of endometriosis.
Supporting Information
S1 Fig. TLR4 expression according to rHMGB-1 treatment- original data.
(PDF)
S2 Fig. Effects of TLR4 inhibition on TLR4 expression following rHMGB-1 treatment–
original data.
(PDF)
S3 Fig. Effects of NF-κB inhibition on TLR4 expression following rHMGB-1 treatment-
original data.
(PDF)
Acknowledgments
This research was supported by the Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Tech-
nology (NRF-2012R1A1A1013167). The Design of study and the experiments were modified
and supported by NRF. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript We specially thank to Ah Leum Kim,
who has supported the experiments thoroughly.
Author Contributions
Conceived and designed the experiments: BSL SKS. Performed the experiments: BHY SJC.
Analyzed the data: SKS BHY. Contributed reagents/materials/analysis tools: YSC SC SKS BHY.
Wrote the paper: BHY SKS.
References
1. Adamson GD, Kennedy SH, Hummelshoj L. Creating solutions in endometirosis: global coolaboration
through the World Endometriosis Research Foundation. J Endometriosis. 2010; 2: 3–6.
HMGB-1 Mediates Inflammation in Human Endometrium
PLOSONE | DOI:10.1371/journal.pone.0148165 February 12, 2016 15 / 17
2. D'Hooghe TM, Debrock S. Endometriosis, retrograde menstruation and peritoneal inflammation in
women and in baboons. Hum Reprod Update. 2002; 8: 84–88. PMID: 11866244
3. Murphy AA, SantanamN, Parthasarathy S. Endometriosis: a disease of oxidative stress? Semin
Reprod Endocrinol. 1998; 16: 263–273. PMID: 10101808
4. Kobayashi H, Higashiura Y, Shigetomi H, Kajihara H. Pathogenesis of endometriosis: the role of initial
infection and subsequent sterile inflammation (Review). Mol Med Rep. 2014; 9: 9–15. doi: 10.3892/
mmr.2013.1755 PMID: 24173432
5. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81:
1–5.
6. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator
of endotoxin lethality in mice. Science. 1999; 285: 248–251. PMID: 10398600
7. Bianchi ME, BeltrameM, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1.
Science. 1989; 243: 1056–1059. PMID: 2922595
8. HuangW, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine. 2010; 51: 119–
126. doi: 10.1016/j.cyto.2010.02.021 PMID: 20347329
9. Guven Maiorov E, Keskin O, Gursoy A, Nussinov R. The structural network of inflammation and cancer:
merits and challenges. Semin Cancer Biol. 2013; 23: 243–251. doi: 10.1016/j.semcancer.2013.05.003
PMID: 23712403
10. Weng H, Deng Y, Xie Y, Liu H, Gong F. Expression and significance of HMGB1, TLR4 and NF-kappaB
p65 in human epidermal tumors. BMC Cancer. 2013; 13: 311. doi: 10.1186/1471-2407-13-311 PMID:
23803172
11. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, et al. The HMGB1/RAGE inflammatory
pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene.
2014; 33: 567–577. doi: 10.1038/onc.2012.631 PMID: 23318458
12. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, BuurmanWA, Griffioen AW.
Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 2013;
32: 363–374. doi: 10.1038/onc.2012.49 PMID: 22391561
13. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Bio-
phys Acta. 2010; 1799: 141–148. doi: 10.1016/j.bbagrm.2009.11.003 PMID: 20123076
14. Dhupar R, Klune JR, Evankovich J, Cardinal J, Zhang M, Ross M, et al. Interferon regulatory factor 1
mediates acetylation and release of high mobility group box 1 from hepatocytes during murine liver
ischemia-reperfusion injury. Shock. 2011; 35: 293–301. doi: 10.1097/SHK.0b013e3181f6aab0 PMID:
20856174
15. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975; 122: 262–
263. PMID: 1155504
16. Bulun SE. Endometriosis. N Engl J Med. 2009; 360: 268–279. doi: 10.1056/NEJMra0804690 PMID:
19144942
17. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril. 2001; 75: 1–10.
PMID: 11163805
18. Chapron C, Chopin N, Borghese B, Foulot H, Dousset B, Vacher-Lavenu MC, et al. Deeply infiltrating
endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod. 2006; 21: 1839–
1845. PMID: 16543256
19. Ngo C, Chereau C, Nicco C, Weill B, Chapron C, Batteux F. Reactive oxygen species controls endome-
triosis progression. Am J Pathol. 2009; 175: 225–234. doi: 10.2353/ajpath.2009.080804 PMID:
19498006
20. Lucidi RS, Witz CA, Chrisco M, Binkley PA, Shain SA, Schenken RS. A novel in vitro model of the early
endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is depen-
dent on the source of endometrial cells. Fertil Steril. 2005; 84: 16–21. PMID: 16009148
21. Gonzalez-Ramos R, Defrere S, Devoto L. Nuclear factor-kappaB: a main regulator of inflammation and
cell survival in endometriosis pathophysiology. Fertil Steril. 2012; 98: 520–528. doi: 10.1016/j.fertnstert.
2012.06.021 PMID: 22771029
22. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of che-
motaxis and apoptosis. Hum Reprod Update. 2013; 19: 406–418. doi: 10.1093/humupd/dmt010 PMID:
23539633
23. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the
novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical
activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus. 2007; 16:
794–802. PMID: 17895302
HMGB-1 Mediates Inflammation in Human Endometrium
PLOSONE | DOI:10.1371/journal.pone.0148165 February 12, 2016 16 / 17
24. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, et al. High
mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003; 254: 375–385.
PMID: 12974876
25. Lee SA, Kwak MS, Kim S, Shin JS. The role of high mobility group box 1 in innate immunity. Yonsei
Med J. 2014; 55: 1165–1176. doi: 10.3349/ymj.2014.55.5.1165 PMID: 25048472
26. Sahu D, Debnath P, Takayama Y, Iwahara J. Redox properties of the A-domain of the HMGB1 protein.
FEBS Lett. 2008; 582: 3973–3978. doi: 10.1016/j.febslet.2008.09.061 PMID: 18996119
27. Seo SK, Yang HI, Lee KE, Kim HY, Cho S, Choi YS, et al. The roles of thioredoxin and thioredoxin-bind-
ing protein-2 in endometriosis. Hum Reprod. 2010; 25: 1251–1258. doi: 10.1093/humrep/deq027
PMID: 20172870
28. Allhorn S, Boing C, Koch AA, Kimmig R, Gashaw I. TLR3 and TLR4 expression in healthy and diseased
human endometrium. Reprod Biol Endocrinol. 2008; 6: 40. doi: 10.1186/1477-7827-6-40 PMID:
18775079
29. Bhutada S, Basak T, Savardekar L, Katkam RR, Jadhav G, Metkari SM, et al. High mobility group box 1
(HMGB1) protein in human uterine fluid and its relevance in implantation. Hum Reprod. 2014; 29: 763–
780. doi: 10.1093/humrep/det461 PMID: 24488797
30. Guo SW. Nuclear factor-kappab (NF-kappaB): an unsuspected major culprit in the pathogenesis of
endometriosis that is still at large? Gynecol Obstet Invest. 2007; 63: 71–97. PMID: 17028437
HMGB-1 Mediates Inflammation in Human Endometrium
PLOSONE | DOI:10.1371/journal.pone.0148165 February 12, 2016 17 / 17
